Fundraising FoxOphthaFund
Venture capitalCharleston · Pre-Seed–Series A
Find your way into OphthaFund
Sign up to see every warm intro you have to OphthaFund
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OphthaFund team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
The firm leverages deep expertise in ophthalmology and biotechnology to invest in specialized companies within these sectors. The team provides value-add support through drug development knowledge and access to a network of investors, partners, and subject matter experts.
Source: firm website, verified Aug 7, 2026.
What they invest in
from 6 of 11 portfolio companiesBiotech ×6Medical Devices ×4Healthtech ×2Deep Tech ×1Digital Health ×1
HQs:United States×5Switzerland×1
Investments · 11 tracked
founders shown can be your intro pathForwardVue Pharma develops a long-acting ORAI1 blocker administered by intravitreal injection to treat retinal neovascular disease, with a target dosing of 1-2 injections per year for durability up to 12 months.
BiotechHealthtechMedical DevicesMobile, US
Alan Franklin(Ophthalmologist, Vitreoretinal Diseases and Surgery)inRAJ MATURI(Director)NEIL DONNENFELD(Director)RUBEN TIMMONS(Director)BARRY BUTLER(Director)AMIR SHOJAEI(Director)
PartnerTom Mather· solo GP
Implicit BioScience develops therapeutic approaches targeting cardioimmunology, specifically using CD14 blockade to modulate immune responses in acute heart attack (STEMI) treatment.
BiotechDeep TechMedical DevicesSeattle, US
Garry Redlich(CEO & MD, Co-founder)inProf. Peter Andrews(Chairman, Co-founder)James Edward Rottsolk(Executive Officer, Director)Marion Koster(Chief Financial Officer and Company Secretary)inBrian William Ziegelaar(Executive Officer)
BoardDaniel David Syrdal(Director)
PartnerTom Mather· solo GP
Biotechnology company developing treatments for ophthalmic diseases, focusing on dry eye through a topical ophthalmology platform.
BiotechSan Francisco, US
Tom Gadek(Founder)inChristopher J. Murphy(Director)Charles O'Neill(Executive Officer, Director)Tanya Shnaydman(Executive Officer)
PartnerTom Mather· solo GP
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)inDavid Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in
BoardAaron Fletcher(Director)in
PartnerTom Mather· solo GP
Co-investorsExSight VenturesInvest MichiganNovartis Venture FundVisionary VenturesBios PartnersInFocus Capital Partners, LLC+3 more
Premark Pharma develops therapeutic candidates for ophthalmologic conditions including blepharitis and dry eye disease.
BiotechDigital HealthMedical Devices
PartnerTom Mather· solo GP
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Advanced Liquid LogicAllysta PharmaceuticalsBlink CNSElucida OncologyEncore PharmaceuticalsMyze
Frequently asked questions
- How many investments has OphthaFund made?
- OphthaFund has 11 tracked investments.
- What stage does OphthaFund invest at?
- OphthaFund invests at the Pre-Seed, Seed, Series A stages.
- What sectors does OphthaFund focus on?
- OphthaFund focuses on Biotech, Healthtech, Medical Devices.
- Where is OphthaFund located?
- OphthaFund is headquartered in Charleston, US.
- Does OphthaFund lead rounds?
- Yes, OphthaFund leads investment rounds.
- Who does OphthaFund co-invest with?
- OphthaFund most often shares deals with ExSight Ventures, Invest Michigan, Michigan Capital Network, among 6 tracked co-investors.
Images
Similar investors
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Excell Partners is an early-stage venture capital firm that invests in high-growth, technology-driven startups, providing hands-on founder support and commercializing university IP across New York State.
Rockies Venture Fund is a platform for early-stage venture capital funds that supports innovative startups, drawing on the deal flow and network of a national community of investors.
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.
Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.